AngioSoma, Inc. Starts SOMA Nutraceuticals, Inc.’s Operations

Houston, TX — (ReleaseWire) — 04/26/2017 — AngioSoma, Inc., (OTCMKTS:SOAN) recently filed its 10K for the period ending September 30, 2016 and its 10Q for the period ending December 31, 2016. AngioSoma, Inc.’s management would like to update its shareholders on recent progress within its 2017 business plan, including starting operations at its SOMA Nutraceuticals, Inc. Read more about AngioSoma, Inc. Starts SOMA Nutraceuticals, Inc.’s Operations[…]

November 2016 Shareholder Presentation

With so many changes at AngioSoma, Inc. over the last month, we wanted to update our September 2016 shareholder presentation to correctly reflect what AngioSoma, Inc. has been doing.  We have made the November 2016 AngioSoma, Inc. Shareholder Presentation available in both the PDF version and embedded here in its Microsoft PowerPoint version:   © 2016 by Read more about November 2016 Shareholder Presentation[…]

AngioSoma, Inc. Acquires Patented Nutraceutical for Muscle Mass Development

MONTGOMERY, Texas — (BUSINESS WIRE, November 17, 2016 09:45 AM Eastern Standard Time) — AngioSoma, Inc. (OTCQB: SOAN) announces that its new subsidiary Soma Nutraceuticals, Inc. is the recipient of intellectual property conveyed by its Chairman Emeritus Dr. David Summers, including a nutraceutical product using either natural or synthetic nicotine in a patented method for Read more about AngioSoma, Inc. Acquires Patented Nutraceutical for Muscle Mass Development[…]

AngioSoma, Inc. to upgrade its OmniCath Patents into OmniCath 2 Atherectomy Catheter

MONTGOMERY, TEXAS (Business Wire, November 4, 2016 at 9:36 AM CST) – AngioSoma, Inc. today announces that it was filing new improvements to its US Patent No. 5,728,129 and five predecessor patents 4,850,957; 4,994,067; 5,087,265; and 5,695,519; all of which will be used as “prior art” to the its newest catheter, the OmniCath® II.  With Read more about AngioSoma, Inc. to upgrade its OmniCath Patents into OmniCath 2 Atherectomy Catheter[…]

Uptick Newswire talks with Dr. David Summers

Released on October 25, 2016, Uptick Newswire’s Jasyn Blair interviewed Dr. Dr. David Summers, AngioSoma, Inc.’s Chairman Emeritus (entitled “Dr. David Summers, AngioSoma Inc., Talks Entering Joint Venture to Commercialize their Signature Product“.  We also make it available here: Other media outlets covering the interview… Investors Hangout (Front Page) iTunes iHeartRADIO Google Play Audio Boom! Read more about Uptick Newswire talks with Dr. David Summers[…]

Dr. Jackie R. See MD joins AngioSoma, Inc.’s Scientific Advisory Board

MONTGOMERY, TEXAS (Business Wire, October 20, 2016) – AngioSoma, Inc. (OTCQB SOAN) is in final negotiations with Dr. Jackie R. See, M.D., F.A.C.C. to join its Scientific Advisory Board.  Dr. See was instrumental in the original development of liposomal PGE-1 and is involved in new, and still experimental, uses of PGE-1 and stem cell treatment Read more about Dr. Jackie R. See MD joins AngioSoma, Inc.’s Scientific Advisory Board[…]

AngioSoma, Inc. Files 3 New Patent Applications on Liprostin™

MONTGOMERY, Texas — (BUSINESS WIRE,October 11, 2016 09:00 AM Eastern Daylight Time) — AngioSoma, Inc. (OTCQB: SOAN) filed three (3) new patent applications associated with Liprostin™, adding to the Company’s product pipeline and supplementing the intellectual property already conveyed by Chairman Emeritus Dr. David P. “Doc” Summers, PhD, FACA. The new patents include transdermal skin Read more about AngioSoma, Inc. Files 3 New Patent Applications on Liprostin™[…]

AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture

MONTGOMERY, Texas–(BUSINESS WIRE)–AngioSoma, Inc. (OTCQB:SOAN) announces a joint venture with La Jolla Capital Partners LLC (‘La Jolla’) focused on the funding and management of US Food and Drug Administration (‘FDA’) Liprostin™ Phase III trials, as well as the licensing of Liprostin™ worldwide thereafter. Liprostin™ is a liposomal encapsulated prostaglandin e1 (‘PGE1’) and is AngioSoma, Inc.’s Read more about AngioSoma, Inc. Announces a Liprostin™ Focused Joint Venture[…]

Shareholder Presentation, September 2016

Many of our current shareholders have many questions as to what AngioSoma, Inc. is doing, so we are making a shareholder presentation available (the PDF version available here) to all of our shareholders.  We intend to update this as we progress in our business plan.   © 2016 by AngioSoma, Inc., all rights reserved.

Angiosoma.com-product - ticker SOAN OTC

AngioSoma, Inc. enters discussions with Nutraceutical Intellectual Property Owners

Montgomery, Texas (September 21, 2016) – AngioSoma, Inc. (the ‘Company‘, ‘we‘, and ‘our‘), announces the formation of the Soma Nutraceuticals, Inc. subsidiary for the acquisition and marketing of proven nutraceutical products, as well as acquisition discussions with multiple proven nutraceutical intellectual properties. Our Chairman Emeritus “Doc” Summers owns some of the proven nutraceutical products we Read more about AngioSoma, Inc. enters discussions with Nutraceutical Intellectual Property Owners[…]